- Home
- CRTO vs RCUS Comparison
CRTO vs RCUS Comparison
Compare CRTO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- RCUS
- Stock Information
- Founded
- CRTO 2005
- RCUS 2015
- Country
- CRTO France
- RCUS United States
- Employees
- CRTO N/A
- RCUS N/A
- Industry
- CRTO Advertising
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- RCUS Health Care
- Exchange
- CRTO Nasdaq
- RCUS Nasdaq
- Market Cap
- CRTO 1.2B
- RCUS 1.2B
- IPO Year
- CRTO 2013
- RCUS 2018
- Fundamental
- Price
- CRTO $22.01
- RCUS $11.53
- Analyst Decision
- CRTO Buy
- RCUS Buy
- Analyst Count
- CRTO 9
- RCUS 8
- Target Price
- CRTO $39.11
- RCUS $20.71
- AVG Volume (30 Days)
- CRTO 280.6K
- RCUS 747.7K
- Earning Date
- CRTO 10-29-2025
- RCUS 11-05-2025
- Dividend Yield
- CRTO N/A
- RCUS N/A
- EPS Growth
- CRTO 44.35
- RCUS N/A
- EPS
- CRTO 2.38
- RCUS N/A
- Revenue
- CRTO $1,946,032,000.00
- RCUS $262,000,000.00
- Revenue This Year
- CRTO N/A
- RCUS N/A
- Revenue Next Year
- CRTO $2.19
- RCUS N/A
- P/E Ratio
- CRTO $9.20
- RCUS N/A
- Revenue Growth
- CRTO N/A
- RCUS 6.07
- 52 Week Low
- CRTO $21.44
- RCUS $6.50
- 52 Week High
- CRTO $47.27
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- CRTO 36.33
- RCUS 61.05
- Support Level
- CRTO $21.44
- RCUS $11.04
- Resistance Level
- CRTO $23.80
- RCUS $12.05
- Average True Range (ATR)
- CRTO 0.79
- RCUS 0.58
- MACD
- CRTO -0.22
- RCUS 0.03
- Stochastic Oscillator
- CRTO 15.00
- RCUS 67.05
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.